Screening and discussion of the film: “Drug$: The price we pay”

21 November 2018
Calgary, Alberta

This session will include a screening of a portion of the new film “Drug$: The price we pay” and include a facilitated discussion of the film’s relevance to the Canadian experience with pharmaceutical policy as well as the film’s accuracy. An abbreviated synopsis of the film is as follows: “With prices as high as $1,000 per pill, many patients are now forced to choose between putting food on the table or purchasing medicine, while pharma companies pocket billions of dollars in profits … ‘DRUG$’ breaks down the intricacies of the drug pricing system by incorporating interviews with patients, prominent policymakers and employees of major pharmaceutical and insurance companies, as well as highly respected doctors, scientists and economists.”

Film Trailer

Watch the film trailer here:

Screening and discussion of the film: “Drug$: The price we pay”


Reed Beall Profile PictureReed F. Beall is a population health researcher who works largely with medicine patent, regulatory, and utilization data to investigate the long-term impacts of national and international policy decisions which aim to balance incentives between equitable drug innovation and equitable drug access. He is an Assistant Professor in Healthcare Policy in the Department of Community Health Sciences within the Cumming School of Medicine and at the O’Brien Institute for Public Health at the University of Calgary. He also serves as affiliated faculty for the Program on Regulation, Therapeutics, and the Law (PORTAL) based within the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital and Harvard Medical School. He has been invited to provide testimony on his research to the trilateral technical symposium of the World Health Organization, the World Intellectual Property Organization, and the World Trade Organization, as well as to the United Nations Secretary-General's High-Level Panel on Access to Medicines. Dr. Beall’s work has been published in Value in Health, Nature Biotechnology, Health Affairs, PLoS Medicine, and Social Science and Medicine, among others.

The Network of Alberta Health Economists and the NOAHE Health Economics and Technology Assessment Rounds are supported financially and in-kind by Alberta Health, through the Health Funding and Economics Capacity (HFEC) Grant. Please note that the views expressed in this series and other deliverables associated with NOAHE are not necessarily representative of any particular organization involved.